Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 15, 2020 07:00 ET | Source: BeiGene, LTD.

BeiGene Announces Clinical and Preclinical Data to Be Presented at the 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting II

CAMBRIDGE, Mass., and BEIJING, China, May 15, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing...
May 14, 2020 09:00 ET | Source: BeiGene, LTD.

BeiGene Announces Clinical and Non-Clinical Data on BRUKINSA™ (Zanubrutinib) and Tislelizumab to Be Presented at the 25th European Hematology Association (EHA) Virtual Congress

CAMBRIDGE, Mass. and BEIJING, China, May 14, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing...
May 11, 2020 16:05 ET | Source: BeiGene, LTD.

BeiGene Reports First Quarter 2020 Financial Results

CAMBRIDGE, Mass. and BEIJING, China, May 11, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing...
April 29, 2020 17:00 ET | Source: BeiGene, LTD.

BeiGene Announces Clinical Data to Be Presented at the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting

CAMBRIDGE, Mass. and BEIJING, China, April 29, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing...
April 20, 2020 16:05 ET | Source: BeiGene, LTD.

BeiGene Announces Acceptance of a Supplemental New Drug Application for Tislelizumab in Combination with Chemotherapy in First-Line Advanced Squamous Non-Small Cell Lung Cancer in China

BEIJING, China and CAMBRIDGE, Mass., April 20, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing...
April 13, 2020 16:05 ET | Source: BeiGene, LTD.

BeiGene Announces that the Phase 3 Trial of Tislelizumab Combined with Chemotherapy in Patients with First-Line Non-Squamous Non-Small Cell Lung Cancer Met the Primary Endpoint of Progression-Free Survival at Interim Analysis

BEIJING, China, and CAMBRIDGE, Mass., April 13, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing...
April 10, 2020 18:00 ET | Source: BeiGene, LTD.

China National Medical Products Administration Approves BeiGene’s Tislelizumab for Patients with Previously Treated Locally Advanced or Metastatic Urothelial Carcinoma

BEIJING, China and CAMBRIDGE, Mass., April 10, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing...
March 25, 2020 09:00 ET | Source: BeiGene, LTD.

BeiGene Announces Supply Update for ABRAXANE® in China

- NMPA has suspended the importation, sales and use of ABRAXANE in China supplied by Celgene Corporation, a Bristol Myers Squibb (BMS) company - As the marketing agent for ABRAXANE in China, BeiGene...
March 02, 2020 16:05 ET | Source: BeiGene, LTD.

BeiGene Reports Fourth Quarter and Full Year 2019 Financial Results

CAMBRIDGE, Mass. and BEIJING, China, March 02, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and...
February 25, 2020 07:00 ET | Source: BeiGene, LTD.

BeiGene to Present at the Cowen and Company’s 40th Annual Health Care Conference

CAMBRIDGE, Mass. and BEIJING, China, Feb. 25, 2020 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right